A new assessment by think tank GTRI underscores India’s central place in global access to medicines and defends its intellectual property framework as consistent with international trade rules. India produces almost 20% of the world’s generic medicines, supplying both developing and developed countries and helping drive down healthcare costs worldwide.
The spotlight returned to India after the Office of the United States Trade Representative (USTR) placed the country once again on the Priority Watch List in its Special 301 Report published April 30. The designation highlights ongoing U.S. concerns about pharmaceutical-related IP protection and enforcement in India, but GTRI stresses important context: the Special 301 process is an administrative review and not a binding legal mechanism. It serves as a diplomatic and commercial pressure tool that can prompt negotiations or investigations, but it does not itself impose sanctions.
GTRI founder Ajay Srivastava says the core dispute reflects differing policy choices rather than a WTO violation. India maintains that its patent laws comply with the TRIPS agreement, and that the real disagreement is over U.S. demands for TRIPS-plus standards—tighter protections that go beyond WTO obligations. India’s approach prioritizes affordable access to medicines; provisions such as Section 3(d) (which limits patenting of minor modifications) and the option of compulsory licensing are cited as key elements of that balance.
Generics manufactured in India typically lower drug prices dramatically—often by 80–90% compared with brand-name versions—making them essential to reducing medical costs at scale. The country’s export relationship with the U.S. illustrates the practical overlap: in 2025 India shipped about USD 9.7 billion in medicines to the American market, predominantly low-cost generics that help contain healthcare spending.
Srivastava and GTRI warn that acquiescing to stricter, TRIPS-plus demands could undermine India’s generics industry—frequently called the “pharmacy of the world”—and thereby harm patients globally, including in the United States. They note that pressure from U.S. industry interests has shaped this dispute for decades, dating back to the 1990s when India reformed its patent laws to comply with international rules while preserving public health safeguards.
The debate is therefore both legal and political: India asserts WTO compliance and defends policy space to promote access, while critics argue for stronger IP enforcement to protect innovators. GTRI recommends that India continue to defend its balance between innovation incentives and public health priorities, arguing that preserving affordable access to medicines and national policy autonomy remains vital for global health equity.
